---
category: news
title: "BigBear.ai (NYSE:BBAI) Downgraded to Sell at Zacks Investment Research"
excerpt: "BigBear.ai (NYSE:BBAI – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “BigBear."
publishedDateTime: 2022-05-09T21:36:00Z
originalUrl: "https://www.defenseworld.net/2022/05/09/bigbear-ai-nysebbai-downgraded-to-sell-at-zacks-investment-research-2.html"
webUrl: "https://www.defenseworld.net/2022/05/09/bigbear-ai-nysebbai-downgraded-to-sell-at-zacks-investment-research-2.html"
type: article
quality: 17
heat: -1
published: false

provider:
  name: Defense World
  domain: defenseworld.net

topics:
  - AI

related:
  - title: "BigBear.ai Announces First Quarter 2022 Financial Results"
    excerpt: "BigBear.ai Holdings, Inc. (NYSE: BBAI) (“BigBear.ai” or the “Company”), a leader in AI-powered analytics and cyber engineering solutions, today announced financial results for the first quarter of 2022."
    publishedDateTime: 2022-05-09T20:15:00Z
    webUrl: "https://finance.dailyherald.com/dailyherald/article/bizwire-2022-5-9-bigbearai-announces-first-quarter-2022-financial-results"
    type: article
    provider:
      name: Daily Herald
      domain: dailyherald.com
    quality: 17
  - title: "BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights"
    excerpt: "Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Top-line data readout in Q4 2022/early Q1 2023 for TRANQUILITY II Phase 3 trial evaluating BXCL501 in acute treatment of agitation associated with Alzheimer’s disease Extended cash runway into 2025 with $260 million strategic financing for IGALMI commercial launch and clinical and regulatory milestones U."
    publishedDateTime: 2022-05-09T11:03:00Z
    webUrl: "https://apnews.com/press-release/globe-newswire/covid-technology-health-business-mental-3717bf59c739265c231f90dcf287f725"
    type: article
    provider:
      name: Associated Press
      domain: apnews.com
    quality: 10
    images:
      - url: "https://apnews.com/images/PaidContent3.png"
        width: 700
        height: 450
        isCached: true
  - title: "Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights"
    excerpt: "Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology,"
    publishedDateTime: 2022-05-13T12:08:00Z
    webUrl: "https://apnews.com/press-release/business-wire/technology-health-houston-artificial-intelligence-30ce6c45ac424dae9652f7c7d06dac34"
    type: article
    provider:
      name: Associated Press
      domain: apnews.com
    quality: 0

secured: "HGTukhsOu2Q9cGHW75qu1xYTtYNrzaxsY88d6HiFEg2crKv9It69YqeMv8C7ZNukBo4yzjLjmHo6oCbex+Ojco3nWddooxcwZrfi8J6JR7KA/4t9MQJGHAtqF0+8VBxGefaAr7K+K033AYln0DaxAjHLwxHuDEMGqQzaJFpS57zCjcFba+e1BO4nvsHO7ZajElBdggXV6rkotAO0f+tQTg+jH5fJ2RTqBaffO/iIe9T33tHP1ahsJyxsieZrvcN7zLtJluWY3vaG6F6nnyFi5WlPICInkyY/qMSAJUjcdK45lnCWcG7YYCETnkhXXBC/0VVV7WciTAhrRVU09ZMgUEEhyULPuzj0xZV2KnLIkrw=;KmFxnF/Dv978WaKhljcI+g=="
---

